NEA Approved Content
Research in Review
The growing pipeline of therapies for atopic dermatitis has dermatologists optimistic about the future for individuals living with this disease.
Atopic dermatitis (AD), the most common form of eczema, is a chronically relapsing inflammatory skin disease with a complex pathogenesis affecting up to 25% of children in industrialized countries.
Atopic dermatitis (AD) is associated with a heterogeneous presentation and clinical course. However, there is a lack of simple and validated severity assessments that are feasible for clinical practice and epidemiological research, according to researchers of a new study that sought to validate patient-reported global AD severity in adults.